PACS Group, Inc. PACS R2KR3KPHARMA
Company Overview
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. It also provides senior care and independent living facilities. The company engages in the acquisition, ownership, and leasing of health care-related properties. PACS Group, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Why Investors Should Care
Generates a return on equity of 27.9%, reflecting efficient use of shareholder capital.
Revenue has grown at a 30.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $5.29B (+29.4% YoY); net profit $191.54M.
- Trailing 12 Months Year-on-year growth — revenue +9.1%, earnings +51.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 30.1%, profit CAGR 8.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 30.14% |
| 1 Year: | 9.10% |
Compounded Profit Growth
| 5 Years: | 8.37% |
| 1 Year: | 51.60% |
Stock Price Performance
| 1 Year: | +313.76% |
| 6 Months: | +35.52% |
| 3 Months: | +1.39% |
| 1 Month: | +15.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.10 · Neutral
P/E of 27.78 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 27.9%.
- Compounding revenue at 30.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PACS PACS Group, Inc. R2KR3KPHARMA | 47.50 | 27.78 | $7.52B | 0.00% | 6.76% | 27.92% | 30.14% | 8.37% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 707.83M | 760.42M | 788.93M | 919.41M | 935.26M | 1.02B | 1.28B | 1.31B | 1.34B | 1.42B | 1.43B |
| Operating Income | 59.30M | 49.54M | 36.40M | 65.31M | -37.18M | 22.96M | 48.14M | 80.50M | 86.27M | 120.03M | 109.33M |
| Net Income | 37.60M | 21.22M | 19.93M | 34.82M | -31.88M | 15.62M | 28.47M | 50.96M | 52.41M | 80.69M | 76.37M |
| Diluted EPS | 0.29 | 0.16 | 0.15 | 0.27 | -0.21 | 0.10 | 0.17 | 0.31 | 0.32 | 0.50 | 0.47 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 2.40B | 3.11B | 4.09B | 5.29B |
| Operating Income | 229.36M | 207.77M | 123.07M | 309.60M |
| Net Income | 150.50M | 112.87M | 55.76M | 191.54M |
| Diluted EPS | 1.17 | 0.88 | 0.38 | 1.22 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.51B | 3.86B | 3.93B | 5.24B | 5.58B |
| Total Equity | -24.81M | 68.65M | 96.13M | 113.67M | 536.84M | 709.55M | 946.77M |
| Cash & Equivalents | - | 58.27M | 73.42M | 81.21M | 73.37M | 157.67M | 197.02M |
| Long Term Debt | - | - | 195.71M | - | - | 250.98M | 244.80M |
| Total Liabilities | - | - | 3.41B | 3.74B | 3.39B | 4.53B | 4.63B |
| Current Liabilities | - | - | 456.93M | 535.38M | 488.20M | 978.43M | 1.00B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 92.61M | 63.70M | 367.34M | 404.22M |
| Investing Cash Flow | -75.32M | -172.79M | -442.68M | -264.02M |
| Financing Cash Flow | 12.35M | 129.59M | 117.48M | -68.99M |
| Dividends Paid | 60.28M | 80.39M | 33.72M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | 9.6% | 6.7% | 3.0% | 5.9% |
| Net Margin % | 6.3% | 3.6% | 1.4% | 3.6% |
| ROE % | 219.2% | 117.4% | 7.9% | 20.2% |
| ROCE % | - | 6.8% | 2.9% | 6.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cohen & Steers Inc. | 5.27% | 8.34M | $361.27M |
| 2 | FMR, LLC | 3.92% | 6.21M | $268.78M |
| 3 | Blackrock Inc. | 2.63% | 4.16M | $179.93M |
| 4 | Crewe Advisors LLC | 2.09% | 3.31M | $143.20M |
| 5 | American Century Companies Inc | 1.96% | 3.11M | $134.58M |
| 6 | Ameriprise Financial, Inc. | 1.26% | 2.00M | $86.39M |
| 7 | Vanguard Portfolio Management LLC | 1.25% | 1.98M | $85.85M |
| 8 | Vanguard Capital Management LLC | 1.16% | 1.84M | $79.82M |
| 9 | Alyeska Investment Group, L.p. | 0.97% | 1.54M | $66.64M |
| 10 | Dimensional Fund Advisors LP | 0.78% | 1.23M | $53.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PACS
PACS Nov 2026 40.000 call (PACS261120C00040000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5ZVWZvaFgyT2dzSWZ1a2x5LWxNUlJ2dWJWalJ5VFNvVkhRQWExM2FFZjR5ZEJVMzZqYk45eFFjNFAyMG1oWXNfZEttVURrYlRLNERuaEJTNGdhV0wxSXZITW1WcUtrZw?oc=5" target="_blank">PACS Nov 2026 40.000 call (PA…
PACS Group CEO Jason Murray sells $2.18m in company stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOcGdkQTRoM1RZbHdSS09rS3VyYnpVLTRyMlpxbXpUWEhRRjNNeTlOS2dSZVFiUHlZQThQQjZWN1hJdkZpWnZqYVFRMTJmLXZYcWRLN0syWDhTbnRPd1dpWGFXb1hYTEtTWHdXQ1FoY1A2RW5IOE91NlZ1T2lqeWJTY3RENm9BRlE5NThzWC…
Did PACS Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Morningstar
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxONGxLSjZJWVY4NjAwQjBueWY2QkZXLXd0c1F1b09hUTdnc3lMdXI4X2dWaEhrWXhKTlhBR1FKSTFGUjAxcjBKelo4OGdBUzZPaW0xcDQ1VjBnMWh1LWNhSEw0NGFXQU5sSEJUNVVMcGRQaUdpR1BHTE9WYnJaRWxGZkY1aHlQOWVaMkRvX2…
Lease Expansion Could Reshape The Case For PACS Group (PACS) Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOV0wxd0NiWnNTTzc2ZXVlbDNTdGlkcWtxUWF3cHlJSVFHdjZVRW5GOUoyaHBhQmRSQWNpOERVZEFZSzJmR2FoSnkya2x1Zjk0X3dLcXJfOGtsdC01alcybnBDd1lub056Y09zVVdpRkY5amcyTDQxUkYzR0p0TkczTEU3MWlXUEpPZDJrU0…
Pacs Group Insider Sold Shares Worth $5,614,667, According to a Recent SEC Filing - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQcl92N0hLb2R4d2pEcGFndWxoanZJQ2FsWDQzc1d1MzI2azlDZnQtd2h3SFRURmw0WEhsamFEVlluTUZLZTlSc2VORGFlZVR5bGI3bWpkNnFCNUhvdjhhVHQwQWRZNlQtRERsZ1lPMTh4SUNJc0JYaHNuWXY0QjdjcGFyLWdsYk9laGowR0…
PACS Group CEO Hulse sells $5.6m in PACS stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPYVl5eUY0R2p6cGE5UUZ4aHFJT3U3ZEpXQTBpMlc0UGRwWVJ4TlpxM2xkcFNGcmZLOXZnYi1HaTllSW93V0FYVlRrbEZMRk01NlBpRERsUWN6akVaVV9JVW9BdE55ZVRrOEFpZ1NabVJzVWpoa2hMaXhZa3F3eVNwZGhsME9NZDQxa0tDbn…
PACS — Frequently Asked Questions
What is the current share price of PACS Group, Inc. (PACS)?
As of 2026-10-22 16:30 PDT, PACS Group, Inc. (PACS) trades at $47.50 on NYSE. Its 52-week range is $7.71 to $48.45.
What is the market capitalisation of PACS?
PACS Group, Inc. (PACS) has a market capitalisation of $7.52B on NYSE.
What is the P/E ratio of PACS?
PACS trades at a trailing price-to-earnings (P/E) ratio of 27.78. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 6.01.
What is the return on equity (ROE) of PACS?
PACS has a return on equity (ROE) of 27.92%. Its return on capital employed (ROCE) is 6.76%.
Is PACS a good stock to buy?
This page provides a data-driven analysis of PACS Group, Inc. (PACS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.